All In Biotech

Drug Trial Radar · NCT04892173

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 10, 2021

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
May 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Conditions

  • Carcinoma, Squamous Cell

Interventions

  • JNJ-90301900 (NBTXR3)Drug

    Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.

  • CetuximabDrug

    Solution for infusion

  • Radiation TherapyRadiation

    Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Based on Independent Central Review (ICR)Time frame: 30 months following first randomized participant

Locations

196 sites in 27 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • University of California at San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Memorial Radiation Oncology Medical Group Laguna Hills

    Laguna Hills, California · Completed

  • UCLA Hematology Oncology

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California · Completed

  • University of California San Francisco

    San Francisco, California · Recruiting

  • George Washington University Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Christus St. Vincent Regional Cancer Center

    Santa Fe, New Mexico · Completed

  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

    New York, New York · Completed

  • Richmond University Medical Center

    Staten Island, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health And Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Macon Joan Brock Virginia Health Sciences Eastern Virginia Medical Group at Old Dominion University

    Norfolk, Virginia · Recruiting

  • Medizinische Universitat Graz

    Graz, Austria · Completed

  • Medical University Innsbruck

    Innsbruck, Austria · Recruiting

  • Ordensklinikum Linz GmbH Barmherzige Schwestern

    Linz, Austria · Recruiting

  • Medizinische Universitaet Wien

    Vienna, Austria · Recruiting

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium · Recruiting

  • Grand Hopital De Charleroi Site Les Viviers

    Charleroi, Belgium · Completed

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium · Recruiting

  • Fundacao Pio XII

    Barretos, Brazil · Recruiting

  • Nucleo de Ensino e Pesquisa do Instituto Mario Penna

    Belo Horizonte, Brazil · Recruiting

  • Centro Regional Integrado de Oncologia CRIO

    Fortaleza, Brazil · Completed

  • Instituto Do Cancer Do Ceara

    Fortaleza, Brazil · Recruiting

  • Fundacao Sao Francisco Xavier

    Ipatinga, Brazil · Recruiting

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil · Recruiting

  • Hospital do Cancer de Londrina

    Londrina, Brazil · Recruiting

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.